PharmaNutra SpA (IT:PHN)
:PHN
Top Page
PharmaNutra SpA
(PHN)
Select Model
Select Model
Rating:78Outperform
Price Target:
€84.00
▲(9.09% Upside)
Action:ReiteratedDate:03/20/26
The score is driven primarily by strong underlying fundamentals (high margins/ROE and manageable leverage) and supportive technical momentum (price above key moving averages with positive MACD). This is tempered by valuation (P/E ~26 with only ~1.36% yield) and some fundamental quality risks from slowing growth and uneven cash-flow conversion.
Positive Factors
High profitability & returns
Sustained high operating and EBITDA margins plus strong ROE signal durable pricing power and efficient capital use. That margin cushion supports reinvestment, dividend capacity and resilience to cost shocks, underpinning long‑term shareholder return potential even if top‑line slows.
Negative Factors
Slowing revenue momentum
A marked deceleration to single‑digit growth after multi‑year expansion suggests market saturation, tougher competition or weaker product cadence. Persistently slower top‑line reduces capacity to fund organic investment and risks compressing margins or returns if cost structure is fixed.
Read all positive and negative factors
Positive Factors
Negative Factors
High profitability & returns
Sustained high operating and EBITDA margins plus strong ROE signal durable pricing power and efficient capital use. That margin cushion supports reinvestment, dividend capacity and resilience to cost shocks, underpinning long‑term shareholder return potential even if top‑line slows.
Read all positive factors
PharmaNutra SpA (PHN) vs. iShares MSCI Italy ETF (EWI)
Market Cap
€745.44M
Dividend Yield1.86%
Average Volume (3M)25.97K
Price to Earnings (P/E)26.0
Beta (1Y)0.38
Revenue Growth12.82%
EPS Growth7.37%
CountryIT
Employees118
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.62
Shares Outstanding9,680,977
10 Day Avg. Volume12,507
30 Day Avg. Volume25,966
Financial Highlights & Ratios
PEG Ratio1.25
Price to Book (P/B)7.28
Price to Sales (P/S)3.95
P/FCF Ratio31.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€82.67Price Target Upside7.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)2.54
Revenue Forecast (FY)€151.87M
PharmaNutra SpA Business Overview & Revenue Model
Company Description
Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The company also produ...
How the Company Makes Money
PharmaNutra makes money primarily by selling nutraceutical and medical nutrition products through a combination of (i) direct sales of its own branded portfolio and (ii) business-to-business supply/contract activities. A key revenue stream is the ...
PharmaNutra SpA Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
78
Positive
Cash Flow
73
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 131.69M | 116.15M | 101.03M | 83.39M | 68.14M |
| Gross Profit | 29.71M | 82.79M | 48.95M | 30.17M | 32.15M |
| EBITDA | 34.21M | 32.01M | 26.53M | 24.61M | 19.84M |
| Net Income | 20.00M | 16.61M | 12.83M | 15.05M | 13.77M |
Balance Sheet | |||||
| Total Assets | 125.23M | 117.47M | 112.44M | 100.16M | 71.36M |
| Cash, Cash Equivalents and Short-Term Investments | 30.61M | 29.10M | 25.12M | 26.86M | 33.94M |
| Total Debt | 20.51M | 24.27M | 28.02M | 17.73M | 6.35M |
| Total Liabilities | 53.99M | 55.27M | 58.04M | 49.21M | 26.27M |
| Stockholders Equity | 71.35M | 62.16M | 54.41M | 50.95M | 45.08M |
Cash Flow | |||||
| Free Cash Flow | 16.43M | 16.25M | -1.16M | -8.69M | 15.43M |
| Operating Cash Flow | 19.56M | 20.50M | 12.09M | 14.47M | 20.41M |
| Investing Cash Flow | -3.36M | -2.21M | -14.70M | -23.71M | -5.54M |
| Financing Cash Flow | -13.12M | -21.59M | -516.00K | 1.89M | -1.92M |
PharmaNutra SpA Technical Analysis
Positive
77.00
Price Trends
68.02
Positive
61.75
Positive
53.88
Positive
Market Momentum
3.20
Negative
70.37
Negative
82.88
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHN, the sentiment is Positive. The current price of 77 is above the 20-day moving average (MA) of 73.33, above the 50-day MA of 68.02, and above the 200-day MA of 53.88, indicating a bullish trend. The MACD of 3.20 indicates Negative momentum. The RSI at 70.37 is Negative, neither overbought nor oversold. The STOCH value of 82.88 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:PHN.
PharmaNutra SpA Peers Comparison
UnderperformOutperform
Sector (51)
IT:PHN
PharmaNutra SpA
77.00
30.52
65.66%
IT:GHC
Garofalo Health Care S.P.A.
4.68
-0.36
-7.07%
IT:ARBS
Arterra Bioscience SpA
3.05
1.07
54.04%
IT:EUK
Eukedos S.p.A.
0.53
-0.22
-29.33%
IT:COSMO
Farmacosmo S.P.A.
0.49
-0.21
-30.57%
IT:SVS
Svas Biosana S.p.A.
8.42
1.61
23.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.